{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:37:53Z","timestamp":1777505873116,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ejmech.2014.07.060","type":"journal-article","created":{"date-parts":[[2014,7,19]],"date-time":"2014-07-19T18:16:29Z","timestamp":1405793789000},"page":"614-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-2104","authenticated-orcid":false,"given":"Lucia","family":"Squarcialupi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Colotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Catarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Varano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Betti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Varani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Vincenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Andrea","family":"Borea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Ciancetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2014.07.060_bib1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International union of pharmacology XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2014.07.060_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.110.003285","article-title":"International union of pharmacology LXXXI. Nomenclature and classification of adenosine receptors. An up date","volume":"63","author":"Fredholm","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2014.07.060_bib3","series-title":"Purinergic and Pyrimidinergic Signalling","first-page":"129","article-title":"P1 and P2 purine and pyrimidine receptor ligands","volume":"vol. 151\/1","author":"Jacobson","year":"2001"},{"key":"10.1016\/j.ejmech.2014.07.060_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ki.2010.204","article-title":"Adenosine A1 receptor antagonists in clinical research and development","volume":"78","author":"Hocher","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2014.07.060_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2014.07.060_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/14656560802682213","article-title":"Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure","volume":"10","author":"Slawsky","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2014.07.060_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1254\/jphs.FP0040359","article-title":"Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors","volume":"96","author":"Maemoto","year":"2004","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2014.07.060_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbr.2008.06.035","article-title":"A\u00a0novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs","volume":"194","author":"Mihara","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2014.07.060_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1471-4159.2011.07178.x","article-title":"Adenosine A2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction","volume":"117","author":"Rebola","year":"2011","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pneurobio.2007.09.002","article-title":"Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and \u201cfine tuning\u201d modulation","volume":"83","author":"Chen","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2014.07.060_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson's disease","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejmech.2014.07.060_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pharmthera.2011.07.004","article-title":"Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease","volume":"132","author":"Armentero","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2014.07.060_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets \u2014 what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2014.07.060_bib14","series-title":"Approval for Manufacturing and Marketing of NOURIAST Tablets 20\u00a0mg. A Novel Antiparkinsonian Agent","author":"Kyowa Hakko Kirin","year":"2013"},{"key":"10.1016\/j.ejmech.2014.07.060_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-013-3158-x","article-title":"Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex","volume":"230","author":"Horita","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejmech.2014.07.060_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.brainres.2010.08.099","article-title":"Deletion of A1 or A2A receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson\u2019s disease","volume":"1367","author":"Xiao","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2014.07.060_bib17","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.2174\/092986706779026093","article-title":"Potent adenosine A1 and A2A receptor antagonists: recent developments","volume":"13","author":"Yuzlenko","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib18","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/jm991096e","article-title":"1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists","volume":"43","author":"Colotta","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib19","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1021\/jm000936i","article-title":"Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists","volume":"43","author":"Colotta","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib20","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1021\/jm031136l","article-title":"The 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological and ligand-receptor modeling studies","volume":"47","author":"Colotta","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bmc.2004.10.050","article-title":"2-Aryl-8-chloro-1,2,4-triazolo[1,5-a]quinoxalin-4-amines as highly potent A1 and A3 adenosine receptor antagonists","volume":"13","author":"Catarzi","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib22","doi-asserted-by":"crossref","first-page":"7932","DOI":"10.1021\/jm0504149","article-title":"1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives","volume":"48","author":"Catarzi","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib23","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1021\/jm060373w","article-title":"4-Amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies","volume":"49","author":"Lenzi","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib24","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1021\/jm070123v","article-title":"Arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies","volume":"50","author":"Colotta","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib25","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1021\/jm070852a","article-title":"Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine skeleton as a key study","volume":"50","author":"Morizzo","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib26","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.bmc.2008.04.039","article-title":"Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists","volume":"16","author":"Colotta","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bmc.2008.10.018","article-title":"Novel potent and highly selective human A3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series. Molecular docking analysis and pharmacological studies","volume":"17","author":"Colotta","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib28","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1021\/jm8014876","article-title":"Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation and ligand-receptor modeling studies","volume":"52","author":"Colotta","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib29","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1021\/jm900718w","article-title":"2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition","volume":"52","author":"Lenzi","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib30","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1021\/jm101328n","article-title":"The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists","volume":"54","author":"Poli","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib31","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1021\/jm400068e","article-title":"2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent\u00a0and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation","volume":"56","author":"Squarcialupi","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib32","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1021\/ja01260a024","article-title":"the preparation of orthoesters","volume":"64","author":"Mc Elvain","year":"1942","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2014.07.060_bib33","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1016\/j.bmc.2012.01.048","article-title":"Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study","volume":"20","author":"Chorell","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib34","unstructured":"R.F. Clark, N.Y. Ba-Maung, S.A. Erickson, S.D. Fidanze, R.A. Mantei, G.S. Sheppard, B.K. Sorensen, G.T. Wang, J. Wang, R.L. Bell, Preparation of pyrimidine inhibitors of kinase activity, WO2010\/138575 A1, 2010."},{"key":"10.1016\/j.ejmech.2014.07.060_bib35","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/jm970513p","article-title":"Benzylimidazolines as h5-HT1B\/1D serotonin receptor ligands: a structure-affinity investigation","volume":"41","author":"Law","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jlac.1992199201130","article-title":"Isolierung, synthese und biologische wirkung von coniothyriomycin sowie synthese un biotestung analoger offenkettinger imide","author":"Krohn","year":"1992","journal-title":"Liebigs Ann. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib37","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/10020376","article-title":"Synthesis of 4-amino-4,5-dihydro-1H-1,2,4-triazole-5-ones and their isatin-3-imine derivatives","volume":"10","author":"Kahveci","year":"2005","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2014.07.060_bib38","first-page":"21","article-title":"Synthesis and choleretic activity of 3-[2-(3-R\u2032,4-R\u2033,5-R\u2034-benzyl)-5-R-benzimidazol-1-yl]butanoic acids","volume":"47","author":"Grella","year":"1992","journal-title":"Farmaco"},{"key":"10.1016\/j.ejmech.2014.07.060_bib39","unstructured":"F. Almqvist, E. Chorell, P. Das, H. Emtenaes, O. Fjellstroem, M. Mogemark, M. Polla, V. Veronica, 1H-Pyridin-2-one derivatives as PAI-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases, PCT Int. Appl., WO2008054290, A1 20080508, 2008."},{"key":"10.1016\/j.ejmech.2014.07.060_bib40","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3390\/molecules13092126","article-title":"Synthesis of Schiff and Mannich bases of isatin derivatives with 4-amino-4,5-dihydro-1H-1,2,4-triazole-5-ones","volume":"13","author":"Bekircan","year":"2008","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2014.07.060_bib41","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1021\/jo00882a024","article-title":"Some transformations of DL-phenylalanine ortho esters and N-benzyloxycarbonyl-L-phenylalaninal","volume":"41","author":"Zemlicka","year":"1976","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib42","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0960-894X(02)01060-0","article-title":"Novel N1-(Benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists","volume":"13","author":"Curtis","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2014.07.060_bib43","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/00397918408076797","article-title":"Aldolic condensation on inorganic solid support: application to the synthesis of O-ethyl esters of 3-phenyl-2-propenethioic acids","volume":"14","author":"Davrinche","year":"1894","journal-title":"Synth. Comm."},{"key":"10.1016\/j.ejmech.2014.07.060_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/(SICI)1099-1344(199801)41:1<29::AID-JLCR50>3.0.CO;2-E","article-title":"Synthesis of [1-13C] and [1-15N] labelled DL-homophenylalanine via a key Neber rearrangement","volume":"41","author":"Olfield","year":"1998","journal-title":"J.\u00a0Label. Compd. Rad."},{"key":"10.1016\/j.ejmech.2014.07.060_bib45","doi-asserted-by":"crossref","first-page":"7851","DOI":"10.1021\/jm400766k","article-title":"New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in\u00a0vivo","volume":"56","author":"Valhondo","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib46","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1021\/jo00279a014","article-title":"Studies on the synthesis of l-azaspiro[5.5]undecanes related to histrionicotoxin","volume":"54","author":"Venit","year":"1989","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib47","doi-asserted-by":"crossref","first-page":"11125","DOI":"10.1016\/j.tet.2005.09.031","article-title":"Facile preparation of organozinc bromides using electrogenerated highly reactive zinc and its use in cross-coupling reaction","volume":"61","author":"Kurono","year":"2005","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2014.07.060_bib48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/13543776.2012.669375","article-title":"Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands","volume":"22","author":"Federico","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2014.07.060_bib49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1126\/science.1219218","article-title":"Structural basis for allosteric regulation of GPCRs by sodium ions","volume":"337","author":"Liu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2014.07.060_bib50","doi-asserted-by":"crossref","first-page":"13987","DOI":"10.1074\/jbc.270.23.13987","article-title":"Site-directed mutagenesis identified residues involved in ligand recognition in the human A2A adenosine receptor","volume":"270","author":"Kim","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib51","doi-asserted-by":"crossref","first-page":"19056","DOI":"10.1074\/jbc.M110960200","article-title":"Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor","volume":"277","author":"Gao","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2010.07.009","article-title":"Structure-based prediction of subtype-selectivity for adenosine receptor antagonists","volume":"60","author":"Katritch","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2014.07.060_bib53","unstructured":"Molecular Operating Environment (MOE), 2012.10, Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2012."},{"key":"10.1016\/j.ejmech.2014.07.060_bib54","series-title":"MOPAC 7","author":"Stewart","year":"1993"},{"key":"10.1016\/j.ejmech.2014.07.060_bib55","unstructured":"GOLD Suite, Version 5.1, Cambridge Crystallographic Data Centre, Cambridge, U.K. http:\/\/www.ccdc.cam.ac.uk."},{"key":"10.1016\/j.ejmech.2014.07.060_bib56","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejmech.2012.10.022","article-title":"Adenosiland: walking through adenosine receptors landscape","volume":"58","author":"Floris","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib57","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors","volume":"25","author":"Ballesteros","year":"1995","journal-title":"Methods Neurosci."},{"key":"10.1016\/j.ejmech.2014.07.060_bib58","doi-asserted-by":"crossref","DOI":"10.1021\/ci5002857","article-title":"An alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A2A receptor as a case study","author":"Ciancetta","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2014.07.060_bib59","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/0024-3205(96)00311-6","article-title":"Binding thermodynamics at A1 and A2A adenosine receptors","volume":"59","author":"Borea","year":"1996","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2014.07.060_bib60","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1096\/fj.00-0730fje","article-title":"Aberrant amplification of A2A receptor signalling in striatal cells expressing mutant huntigtin","volume":"15","author":"Varani","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2014.07.060_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0024-3205(98)00289-6","article-title":"Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors","volume":"63","author":"Varani","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2014.07.060_bib62","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.bcp.2005.08.018","article-title":"Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors","volume":"70","author":"Varani","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.07.060_bib63","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A\u00a0rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2014.07.060_bib64","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationships between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2014.07.060_bib65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/0003-2697(80)90515-1","article-title":"Ligand: a versatile computerized approach for the characterization of ligand binding systems","volume":"107","author":"Munson","year":"1980","journal-title":"Anal. Biochem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523414006758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523414006758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T21:48:40Z","timestamp":1746308920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523414006758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":65,"alternative-id":["S0223523414006758"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.07.060","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A1 and A2A adenosine receptors. Molecular modeling and pharmacological studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2014.07.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}